Hims and Hers Stock Drops Despite Launch of New Low Cost Weight Loss Pill
Hims and Hers shares fell yesterday despite the launch of a cheap weight-loss pill. The stock dropped further after the FDA warned against copycat drugs.
Insights:
Hims & Hers Health, Inc. announced on February 6, 2026, a $49-per-month introductory price for a discounted compounded version of the Wegovy weight-loss pill, a product originally developed by Novo Nordisk A/S . The announcement, which took place in the US 
US, produced immediate stock volatility and prompted both regulatory and legal responses. This development is significant as it directly affected market pricing perceptions and triggered a public enforcement comment from marty makary, the head of the U.S. Food and Drug Administration, alongside a legal threat from the Danish pharmaceutical company Novo Nordisk A/S , which is based in DK 
DK.
US, produced immediate stock volatility and prompted both regulatory and legal responses. This development is significant as it directly affected market pricing perceptions and triggered a public enforcement comment from marty makary, the head of the U.S. Food and Drug Administration, alongside a legal threat from the Danish pharmaceutical company Novo Nordisk A/S , which is based in DK DK.
